Stocks in Focus on April 23: Indus Tower, Rallis, Lupin, Gland Pharma to Banks; here are the 5 Newsmakers of the Day

Domestic equity benchmarks ended near the day's high on Thursday, April 22, 2021, amid positive global cues. The S&P BSE Sensex rose 374.87 points, or 0.79 per cent, to close at 48,080.67. The Nifty 50 index added 109.75 points, or 0.77 per cent, to settle at 14,406.15. But certain stocks came in the news after the market was closed. These stocks can impact the indices when it reopens on Thursday, April 22, 2021. List of such five stocks:

See Zee Business Live TV Streaming Below:

Indus Towers: India's largest mobile tower installation company has reported a 0.3% QoQ rise in consolidated profit at Rs 1,364 crore for the quarter ended March 31, 2021. It had posted a net profit of Rs 1,360 crore in the previous quarter ended December 31, 2021. Consolidated revenue dropped by 3.6% QoQ to Rs 4,692 crore as compared to Rs 6,736 crore posted in the previous quarter. EBITDA stood at Rs 3,413 crore in the reported quarter, down 5.4% from Rs 3,608 crore posted in Q3FY21. The margin dropped by 1% to 52.6% in Q4FY21 as compared to Rs 53.6% posted in Q3FY21. 

Rallis (NAKK) + Cyient + Tata Elxsi + Visaka 

Rallis India: The chemical manufacturing company has reported 11 times YoY jump in the consolidated profit at Rs 8 crore in the quarter ended March 31, 2021. It had posted a net profit of Rs 0.7 crore in the same quarter last year. Consolidated revenue grew 36.1% to Rs 471 crore in the reported quarter as compared to Rs 346 crore posted in the same quarter last year. EBITDA stood at Rs 18 crore against a negative EBITDA of Rs 10 crore posted last year. Besides, the board has recommended a dividend of Rs 3 per share. 
Cyient: The digital engineering and technology company has reported an 8% QoQ rise in the consolidated profit at Rs 103 crore for the quarter ended March 31, 2021 (Q4FY21). It had posted a net profit of Rs 95.4 crore in the quarter ended December 31, 2020 (Q3FY21). Consolidated revenue increased by 4.7% to Rs 1,093 crore in the reported quarter against Rs 1,044 crore posted in the previous quarter. In dollar terms, the Hyderabad-based company’s revenue grew 6% to $15 crore against $14.15 crore posted in the previous quarter. EBIT stood fell 8.5% to Rs 105.2 crore as compared to Rs 115 crore posted in the previous quarter. The margins contracted to 9.6% in Q4FY21 as against 11% posted in Q3FY21. 
Tata Elxsi: The design and technology service provider across industries has reported a 13.1% QoQ rise in consolidated profit at Rs 46.5 crore for the quarter ended March 31, 2021 (Q4FY21). It had reported a profit of Rs 41.1 crore in the quarter ended December 31, 2020 (Q3FY21). Consolidated revenue grew 6.7% to Rs 525 crore as compared to Rs 492 crore posted in the previous quarter. EBIT stood at Rs 163 crore, up 10.7% from Rs 147.3 crore posted in the December quarter. The margins improved to 31% in Q4FY21 against 29.9% posted in Q3FY21. Besides, the board has recommended a final dividend of Rs 24 per share for FY21 and a one-time special dividend of Rs 24 per share. It has also recommended the appointment of Gaurav Bajaj as CFO Designate. 

Visaka Industries: The cement roofing sheet manufacturer has reported a 342.9% YoY rise in consolidated profit at Rs 31 crore for the quarter ended March 31, 2021. It had posted a net profit of Rs 7 crore in the same quarter of the last financial year. Consolidated revenue grew 55.3% to Rs 354 crore as compared to Rs 228 crore posted last year. EBITDA grew 150% to Rs 52.5 crore as compared to Rs 21 crore posted in Q4FY20. The margins improved to 14.8% in Q4FY21 as compared to 9.2% posted in Q4FY20. Besides, the board has approved a final dividend of Rs 10 per share. It also - final dividend: 10/share approved the expansion of AC division at Raebareli unit by setting up the additional line with a capacity of 1.00 lakh TPA. 

Nazara Technologies: India based diversified gaming and sports media platform has released its FY21 business update and reported an 84% rise in revenue at Rs 454 crore against Rs 248 crore posted last year. EBITDA grew 5 times to Rs 54 crore against Rs 9.5 crore, while the margin improved 12% in FY21 against 4% in FY20. Also, the board approved the constitution of the risk management committee. It also gave approval to Halaplay Tech for raising upto Rs 18 crore through equity.

Lupin + Gland Pharma + Strides

Lupin: Novitium gets approval from USFDA for the generic use of Famotidine oral suspension. Till now only Lupine supplied it. It has a 12-15% contribution to the total US revenue of the company. 

Gland Pharma: US FDA approval for Foscarnet Sodium Injection, 6000 mg/250 mL (24 mg/mL) Single-Dose Bag for Infusion. Generic Foscarnet Sodium Injection is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Foscavir® Injection, 24 mg/mL, of Clinigen Healthcare Limited. With this approval, Gland Pharma secured the first generic offering status Single-Dose Bag for Infusion. The Foscarnet Sodium Injection, 6000 mg/250 mL (24 mg/mL) and its generic equivalents had US sales of approximately USD 28 million for twelve months ending in January 2021, according to IQVIA.

Strides Pharma: PE firms Carlyle Group, KKR, Advent and Baring Asia are in talks with promoters to buy 30% promoters stakes for a consideration of Rs 2,500 crore, published reports. 

Banks + PSU Banks

Banks in Focus: RBI directs banks to pay dividend upto 50% dividend in FY21. 

PSU Banks: Center can use the challenge method for the sale of assets and it had a discussion on incentive scheme with NITI Aayog and DIPAM. The state government will be incentivized for asset monetization. The cost of monetizing and packaging the asset will be refunded. The state will be incentivized under the challenge method. Three states that have the most assets will be incentivized for monetization